Adjuvant therapy for melanoma: A surgical perspective

Surgical Oncology Clinics of North America

Volumn 20, Issue 1, 2011, Pages 105-114

  Sondak, Vernon K ^a,b   Gonzalez, Ricardo J ^a,b   Kudchadkar, Ragini ^a,b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Adjuvant therapy; GM CSF; Interferon; Ipilimumab; Melanoma; Vaccines

Indexed keywords

ALPHA2B INTERFERON; CISPLATIN; DACARBAZINE; GANGLIOSIDE ANTIBODY; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERFERON; INTERLEUKIN 2; IPILIMUMAB; MELPHALAN; PEGINTERFERON ALPHA2B; PEPTIDE VACCINE; PLACEBO; VINBLASTINE;

CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONTINUOUS INFUSION; DISEASE FREE SURVIVAL; DISTANT METASTASIS; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; HUMAN; HYPERTHERMIC THERAPY; IN-TRANSIT METASTASIS; LOW DRUG DOSE; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MELANOMA; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SURVIVAL TIME; TREATMENT RESPONSE; TUMOR VOLUME; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; CANCER VACCINES; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOTHERAPY; INTERFERON ALFA-2A; LYMPH NODES; MELANOMA; NEOPLASM RECURRENCE, LOCAL; POLYETHYLENE GLYCOLS; RISK ASSESSMENT; SKIN NEOPLASMS;

EID: 78649486422     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soc.2010.09.001     Document Type: Review

References (46)

1. Kilbridge K.L., Weeks J.C., Sober A.J., et al. Patient preferences for adjuvant interferon alfa-2b treatment. J Clin Oncol 2001, 19:812-823.
2. Riker A.I., Glass F., Perez I., et al. Cutaneous melanoma: methods of biopsy and definitive surgical excision. Dermatol Ther 2005, 18:387-393.
3. Morton D.L., Thompson J.F., Cochran A.J., et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 2006, 355:1307-1317.
4. Balch C.M., Morton D.L., Gershenwald J.E., et al. Sentinel node biopsy and standard of care for melanoma. J Am Acad Dermatol 2009, 60:872-875.
5. Sarnaik A.A., Puleo C.A., Zager J.S., et al. Limiting the morbidity of inguinal lymphadenectomy for metastatic melanoma. Cancer Control 2009, 16:240-247.
6. Balch C.M., Soong S.-J., Gershenwald J.E., et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001, 19:3622-3634.
7. van Akkooi A.C., de Wilt J.H., Verhoef C., et al. Clinical relevance of melanoma micrometastases (<0.1 mm) in sentinel nodes: are these nodes to be considered negative?. Ann Oncol 2006, 17:1578-1585.
8. Ollila D.W., Ashburn J.H., Amos K.D., et al. Metastatic melanoma cells in the sentinel node cannot be ignored. J Am Coll Surg 2009, 208:924-929.
9. Henderson M.A., Burmeister B., Thompson J.F. Adjuvant radiotherapy and regional lymph node field control after lymphadenectomy: results of an intergroup randomized trial (ANZMTG 01.01/TROG 02.01). J Clin Oncol 2009, 27(18S, Suppl 20):LBA9084.
10. Agrawal S., Kane J.M., Guadagnolo B.A., et al. The benefits of adjuvant radiation therapy after therapeutic lymphadenectomy for clinically advanced, high-risk, lymph node-metastatic melanoma. Cancer 2009, 115:5836-5844.
11. McLoughlin J.M., Zager J.S., Sondak V.K. Cytoreductive surgery for melanoma. Surg Oncol Clin N Am 2007, 16:683-693.
12. Kirkwood J.M., Sondak V.K., Hersey P., et al. Adjuvant systemic therapy for high-risk melanoma patients. Cutaneous melanoma 2009, 669-692. Quality Medical Publishing, St Louis (MO). 5th edition. C.M. Balch, A.N. Houghton, A.J. Sober (Eds.).
13. Kirkwood J.M., Strawderman M.H., Ernstoff M.S., et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Group trial EST 1684. J Clin Oncol 1996, 14:7-17.
14. Kirkwood J.M., Manola J., Ibrahim J., et al. A pooled analysis of ECOG and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 2004, 10:1670-1677.
15. Chapman P.B. Counterpoint: the case against adjuvant high-dose interferon-alpha for melanoma patients. J Natl Compr Canc Netw 2004, 2:69-72.
16. Kirkwood J.M., Ibrahim J.G., Sondak V.K., et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 2000, 18:2444-2454.
17. Kirkwood J.M., Ibrahim J.G., Sosman J.A., et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of Intergroup trial E1694/S9512/C509801. J Clin Oncol 2001, 19:2370-2380.
18. Eggermont A.M. Vaccine trials in melanoma-time for reflection. Nat Clin Pract Oncol 2009, 6:256-258.
19. Eggermont A.M., Suciu S., Rutkowski P., et al. Randomized phase III trial comparing postoperative adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation in stage II (T3-T4N0M0) melanoma: final results of study EORTC 18961. J Clin Oncol 2010, 28(15S):612s.
20. Mocellin S., Pasquali S., Rossi C.R., et al. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 2010, 102:493-501.
21. Eggermont A.M., Suciu S., Santinami M., et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 2008, 372:117-126.
22. Sondak V.K., Flaherty L.E. Adjuvant therapy of melanoma: is pegylated interferon alfa-2b what we've been waiting for?. Lancet 2008, 372:89-90.
23. Sondak V.K., Liu P.Y., Tuthill R.J., et al. Adjuvant immunotherapy of resected, intermediate-thickness node-negative melanoma with an allogeneic tumor vaccine. Overall results of a randomized trial of the Southwest Oncology Group. J Clin Oncol 2002, 20:2058-2066.
24. Spitler L.E., Grossbard M.L., Ernstoff M.S., et al. Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor. J Clin Oncol 2000, 18:1614-1621.
25. Daud A.I., Mirza N., Lenox B., et al. Phenotypic and functional analysis of dendritic cells and clinical outcome in patients with high risk melanoma treated with adjuvant GM-CSF. J Clin Oncol 2008, 26:3235-3241.
26. Lawson D.H., Lee S.J., Tarhini A.A., et al. E4697: phase III trial cooperative group study of yeast-derived granulocyte macrophage colony-stimulating factor (GM-CSF) versus placebo as adjuvant treatment of patients with completely resected stage III-IV melanoma. J Clin Oncol 2010, 28(15S):612s.
27. Phan G.Q., Weber J.S., Sondak V.K. CTLA-4 blockade with monoclonal antibodies in patients with metastatic cancer: surgical issues. Ann Surg Oncol 2008, 15:3014-3021.
28. Eton O., Legha S.S., Bedikian A.Y., et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol 2002, 20:2411-2414.
29. Lewis K.D., Robinson W.A., McCarter M., et al. Phase II multicenter study of neoadjuvant biochemotherapy for patients with stage III malignant melanoma. J Clin Oncol 2006, 24:3157-3163.
30. Moschos S.J., Edington H.D., Land S.R., et al. Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J Clin Oncol 2006, 24:3164-3171.
31. Klopp C.T., Alford T.C., Bateman J., et al. Fractionated intra-arterial cancer chemotherapy with methyl bis-amine hydrochloride: a preliminary report. Ann Surg 1950, 132:811-832.
32. Creech O., Ryan R.F., Krementz E.T. Treatment of melanoma by isolation-perfusion technique. J Am Med Assoc 1959, 169:339-343.
33. Stehlin J.S. Hyperthermic perfusion with chemotherapy for cancers of the extremities. Surg Gynecol Obstet 1969, 129:305-308.
34. Fraker D.L. Management of in-transit melanoma of the extremity with isolated limb perfusion. Curr Treat Options Oncol 2004, 5:173-184.
35. Thompson J.F., Kam P.C. Isolated limb infusion for melanoma: a simple but effective alternative to isolated limb perfusion. J Surg Oncol 2004, 88:1-3.
36. Siemann D.W., Chapman M., Beikirch A. Effects of oxygenation and pH on tumor cell response to alkylating chemotherapy. Int J Radiat Oncol Biol Phys 1991, 20:287-289.
37. Brady M.S., Brown K., Patel A., et al. A phase II trial of isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft tissue sarcoma of the extremity. Ann Surg Oncol 2006, 13:1123-1129.
38. Beasley G.M., Caudle A., Petersen R.P., et al. A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US. J Am Coll Surg 2009, 208:706-715.
39. Martijn H., Schraffordt Koops H., Milton G.W., et al. Comparison of two methods of treating primary malignant melanomas Clark IV and V, thickness 1.5 mm and greater, localized on the extremities. Wide surgical excision with and without adjuvant regional perfusion. Cancer 1986, 57:1923-1930.
40. Franklin H.R., Schraffordt Kroops H., Oldhoff J., et al. To perfuse or not to perfuse? a retrospective comparative study to evaluate the effect of adjuvant isolated regional perfusion in patients with stage I extremity melanoma with a thickness of 1.5 mm or greater. J Clin Oncol 1988, 6:701-708.
41. Koops H.S., Vaglini M., Suciu S., et al. Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. J Clin Oncol 1998, 16:2906-2912.
42. Santillan A.A., Delman K.A., Beasley G.M., et al. Predictive factors of regional toxicity and serum creatine phosphokinase levels after isolated limb infusion for melanoma: a multi-institutional analysis. Ann Surg Oncol 2009, 16:2570-2578.
43. Kirkwood J.M., Tarhini A.A. Biomarkers of therapeutic response in melanoma and renal cell carcinoma: potential inroads to improved immunotherapy. J Clin Oncol 2009, 27:2583-2585.
44. Ge D., Fellay J., Thompson A.J., et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461:399-401.
45. Smalley K.S., Nathanson K.L., Flaherty K.T. Genetic subgrouping of melanoma reveals new opportunities for targeted therapy. Cancer Res 2009, 69:3241-3244.
46. Smalley K.S.M., Sondak V.K. Melanoma: the unlikely poster child for personalized cancer therapy?. N Engl J Med 2010, 363:876-878.